GNOM — Global X Genomics & Biotechnology ETF
Data updated: 2026-07-29
GNOM — Global X Genomics & Biotechnology ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $55.79M AUM · 0.50% expense ratio · 61.8% 1-yr return. From SEC regulatory filings.
GNOM Fund Overview
GNOM — Global X Genomics & Biotechnology ETF is a US ETF managed by Global X Funds, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Global X Funds
- Category: United States Health Care Equity
- Assets under management: $55.79M
- 1-year return: 61.8%
- Ticker: GNOM
- SEC CIK: 0001432353
- SEC series ID: S000062676
- Share class ID: C000203266
GNOM Holdings
Top 10 holdings of Global X Genomics & Biotechnology ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Guardant Health, Inc. | 5.59% |
| Illumina, Inc. | 4.82% |
| Natera, Inc. | 4.15% |
| Biomarin Pharmaceutical Inc. | 4.09% |
| Arrowhead Pharmaceuticals, Inc. | 4.07% |
| Legend Biotech Corp | 4.05% |
| Praxis Precision Medicines Inc | 4.01% |
| Twist Bioscience Corp | 3.97% |
| Vertex Pharmaceuticals Incorporated | 3.95% |
| CRISPR Therapeutics AG | 3.85% |
GNOM Portfolio Allocation
Asset-class allocation of Global X Genomics & Biotechnology ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 3.0% |
GNOM Performance
Total returns for GNOM (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 8.1% |
| 1 year | 61.8% |
| 3 years (annualised) | 1.0% |
| 5 years (annualised) | -10.2% |
GNOM Risk Information
Risk metrics for GNOM, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 21.5%
GNOM Costs and Fees
GNOM costs about $50 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.50%
- Gross expense ratio: 0.50%
- Portfolio turnover: 34%
- Brokerage commissions: 2.16 bps of average net assets (SEC N-CEN)
GNOM Cashflows
Over the 12 months to 2026-02, Global X Genomics & Biotechnology ETF had net outflows of $21.20M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$1.88M |
| 2026-01 | −$1.94M |
| 2025-12 | $0 |
| 2025-11 | −$1.16M |
| 2025-10 | $0 |
| 2025-09 | −$2.13M |
GNOM Debt Constituents
No individual debt constituents are reported in Global X Genomics & Biotechnology ETF's latest SEC N-PORT filing.
GNOM Prospectus and SEC Filings
Official Global X Genomics & Biotechnology ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.